chr9-95249255-G-A
Variant summary
Our verdict is Pathogenic. The variant received 16 ACMG points: 16P and 0B. PVS1PP5_Very_Strong
The NM_000136.3(FANCC):c.37C>T(p.Gln13*) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000496 in 1,614,012 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Consequence
NM_000136.3 stop_gained
Scores
Clinical Significance
Conservation
Publications
- Fanconi anemia complementation group CInheritance: AR Classification: DEFINITIVE, STRONG Submitted by: ClinGen, Labcorp Genetics (formerly Invitae), G2P, Myriad Women’s Health
- Fanconi anemiaInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
- colorectal cancerInheritance: AD Classification: LIMITED Submitted by: Ambry Genetics
- malignant pancreatic neoplasmInheritance: AD Classification: LIMITED Submitted by: Ambry Genetics
- ovarian cancerInheritance: AD Classification: LIMITED Submitted by: Ambry Genetics
- prostate cancerInheritance: AD Classification: LIMITED Submitted by: Ambry Genetics
- breast cancerInheritance: AD Classification: NO_KNOWN Submitted by: Ambry Genetics
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 16 ACMG points.
Variant Effect in Transcripts
ACMG analysis was done for transcript: NM_000136.3. You can select a different transcript below to see updated ACMG assignments.
RefSeq Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| FANCC | NM_000136.3 | MANE Select | c.37C>T | p.Gln13* | stop_gained | Exon 2 of 15 | NP_000127.2 | ||
| FANCC | NM_001243743.2 | c.37C>T | p.Gln13* | stop_gained | Exon 2 of 15 | NP_001230672.1 | |||
| FANCC | NM_001243744.2 | c.37C>T | p.Gln13* | stop_gained | Exon 2 of 14 | NP_001230673.1 |
Ensembl Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| FANCC | ENST00000289081.8 | TSL:1 MANE Select | c.37C>T | p.Gln13* | stop_gained | Exon 2 of 15 | ENSP00000289081.3 | ||
| FANCC | ENST00000375305.6 | TSL:1 | c.37C>T | p.Gln13* | stop_gained | Exon 2 of 15 | ENSP00000364454.1 | ||
| FANCC | ENST00000490972.7 | TSL:1 | c.37C>T | p.Gln13* | stop_gained | Exon 2 of 14 | ENSP00000479931.1 |
Frequencies
GnomAD3 genomes AF: 0.00000657 AC: 1AN: 152178Hom.: 0 Cov.: 32 show subpopulations
GnomAD2 exomes AF: 0.00000797 AC: 2AN: 250918 AF XY: 0.00000737 show subpopulations
GnomAD4 exome AF: 0.00000479 AC: 7AN: 1461834Hom.: 0 Cov.: 31 AF XY: 0.00000688 AC XY: 5AN XY: 727222 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.00000657 AC: 1AN: 152178Hom.: 0 Cov.: 32 AF XY: 0.0000135 AC XY: 1AN XY: 74338 show subpopulations
Age Distribution
ClinVar
Submissions by phenotype
Fanconi anemia complementation group C Pathogenic:7Other:1
This submission and the accompanying classification are no longer maintained by the submitter. For more information on current observations and classification, please contact variantquestions@myriad.com.
Variant summary: FANCC c.37C>T (p.Gln13X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory (eg. c.65G>A, p.Trp22X; c.553C>T, p.Arg185X; c.1642C>T, p.Arg548X). The variant allele was found at a frequency of 8.1e-06 in 245648 control chromosomes (gnomAD). This frequency is not significantly higher than expected for a pathogenic variant in FANCC causing Fanconi Anemia Group C (8.1e-06 vs 1.80E-03), allowing no conclusion about variant significance. c.37C>T has been reported in the literature in multiple individuals affected with Fanconi Anemia Group C (De Rocco_2014, Gillio_1997, Susswein_2015). These data indicate that the variant is very likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Three clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.
Curator: Arleen D. Auerbach. Submitter to LOVD: Arleen D. Auerbach.
Common in northern Europeans
Fanconi anemia Pathogenic:2
This sequence change creates a premature translational stop signal (p.Gln13*) in the FANCC gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in FANCC are known to be pathogenic (PMID: 17924555). This variant is present in population databases (rs121917784, gnomAD 0.003%). This premature translational stop signal has been observed in individual(s) with Fanconi anemia (PMID: 8103176, 8128956, 9207444, 26740942). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. This variant is also known as c.292C>T. ClinVar contains an entry for this variant (Variation ID: 12046). For these reasons, this variant has been classified as Pathogenic.
FANCC-related disorder Pathogenic:1
The FANCC c.37C>T variant is predicted to result in premature protein termination (p.Gln13*). This variant is alternatively referred to as 292C>T in literature. It has been reported in the compound heterozygous or homozygous state in several individuals with Fanconi anemia (Verlander et al. 1994. PubMed ID: 8128956; Gillio et al. 1997. PubMed ID: 9207444). It has also been reported in an individual with diffuse B-cell lymphoma (Table S2A, Huang et al. 2018. PubMed ID: 29625052) and in one individual with breast cancer (Table S1, Susswein et al. 2015. PubMed ID: 26681312). This variant is reported in 0.0029% of alleles in individuals of Latino descent in gnomAD and is interpreted as pathogenic/likely pathogenic in ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/variation/12046/). Nonsense variants in FANCC are expected to be pathogenic. This variant is interpreted as pathogenic.
not provided Pathogenic:1
Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); Observed in the heterozygous state in individuals with breast and other cancers referred for genetic testing at GeneDx; This variant is associated with the following publications: (PMID: 17384215, 8103176, 8844212, 24584348, 26596371, 12552564, 8128956, 29922827, 26740942, 12670332, 20869034, 12393516, 10666230, 15516848, 9207444, 26681312, 8639804, 31937788, 29625052, 31589614)
Hereditary cancer-predisposing syndrome Pathogenic:1
The p.Q13* pathogenic mutation (also known as c.37C>T), located in coding exon 1 of the FANCC gene, results from a C to T substitution at nucleotide position 37. This changes the amino acid from a glutamine to a stop codon within coding exon 1. This alteration has been reported in the homozygous and compound heterozygous state in multiple individuals with a clinical diagnosis of Fanconi anemia (Verlander PC et al. Am. J. Hum. Genet., 1994 Apr;54:595-601; Murer-Orlando M et al. Lancet, 1993 Sep;342:686; Gillio AP et al. Blood, 1997 Jul;90:105-10; Nicchia E et al. Mol Genet Genomic Med, 2015 Nov;3:500-12). In addition to the information presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation.
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at